Related Experiment Video
Updated: Oct 12, 2025
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Quantitative Analysis of Cell Aggregation Dynamics Identifies HDAC Inhibitors as Potential Regulators of Cancer Cell
Fabien Gava1, Julie Pignolet1, Sébastien Déjean2
1Institut des Technologies Avancées en Sciences du Vivant (ITAV)-USR3505, Université de Toulouse, CNRS, Université Paul Sabatier, 31100 Toulouse, France.
Abstract:
Characterization of the molecular mechanisms involved in tumor cell clustering could open the way to new therapeutic strategies. Towards this aim, we used an in vitro quantitative procedure to monitor the anchorage-independent cell aggregation kinetics in a panel of 25 cancer cell lines. The analysis of the relationship between selected aggregation dynamic parameters and the gene expression data for these cell lines from the CCLE database allowed identifying genes with expression significantly associated with aggregation parameter variations. Comparison of these transcripts with the perturbagen signatures from the Connectivity Map resource highlighted that they were strongly correlated with the transcriptional signature of most histone deacetylase (HDAC) inhibitors. Experimental evaluation of two HDAC inhibitors (SAHA and ISOX) showed that they inhibited the initial step of in vitro tumor cell aggregation. This validates our findings and reinforces the potential interest of HDCA inhibitors to prevent metastasis spreading.
Insights
Understanding tumor cell clustering mechanisms can lead to new cancer therapies. Histone deacetylase (HDAC) inhibitors were found to significantly reduce tumor cell aggregation, offering potential to prevent metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Tumor cell clustering is a critical step in metastasis.
- Understanding the molecular drivers of cell aggregation is key to developing anti-metastatic therapies.
Purpose of the Study:
- To identify molecular mechanisms regulating cancer cell aggregation.
- To explore the potential of targeting these mechanisms for therapeutic intervention.
Main Methods:
- Quantitative in vitro assay to monitor anchorage-independent cancer cell aggregation kinetics across 25 cell lines.
- Analysis of gene expression data (CCLE database) correlated with aggregation parameters.
- Comparison with perturbagen signatures (Connectivity Map) to identify drug targets.
Main Results:
- Identified specific genes significantly associated with variations in cancer cell aggregation dynamics.
- Found a strong correlation between these genes and the transcriptional signatures of histone deacetylase (HDAC) inhibitors.
- Experimental validation confirmed that two HDAC inhibitors (SAHA, ISOX) inhibit initial tumor cell aggregation in vitro.
Conclusions:
- Molecular mechanisms underlying tumor cell clustering are linked to HDAC inhibitor activity.
- HDAC inhibitors show promise as a therapeutic strategy to inhibit cancer cell aggregation and prevent metastasis.
